Mn Services Vermogensbeheer B.V. Acquires 1,900 Shares of Insulet Corporation $PODD

Key Points

• Mn Services Vermogensbeheer B.V. increased its stake in Insulet Corporation by 7.5%, purchasing an additional 1,900 shares and holding a total of 27,300 shares worth approximately $8.58 million as of the recent quarter.
• Several institutional investors have significantly boosted their holdings in Insulet, with GAMMA Investing LLC increasing its stake by 27,298.6% to over 664,000 shares valued at around $1.74 billion.
• Insulet's stock performance has been strong, with a recent earnings report revealing $649.1 million in revenue, surpassing estimates and reflecting a year-over-year revenue increase of 32.9%.

Mn Services Vermogensbeheer B.V. lifted its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 7.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,300 shares of the medical instruments supplier's stock after buying an additional 1,900 shares during the period. Mn Services Vermogensbeheer B.V.'s holdings in Insulet were worth $8,577,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Larson Financial Group LLC grew its position in Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock valued at $26,000 after acquiring an additional 81 shares during the last quarter. Zions Bancorporation National Association UT bought a new position in shares of Insulet during the 1st quarter valued at $26,000. SouthState Corp raised its position in Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after purchasing an additional 76 shares during the period. Ramirez Asset Management Inc. bought a new stake in Insulet in the first quarter worth $53,000. Finally, NewEdge Advisors LLC lifted its stake in Insulet by 44.8% in the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier's stock worth $54,000 after purchasing an additional 64 shares during the last quarter.

Insulet Stock Up 1.2%

NASDAQ:PODD traded up $3.95 during trading hours on Monday, reaching $334.79. 188,432 shares of the company traded hands, compared to its average volume of 747,317. The stock has a market capitalization of $23.57 billion, a P/E ratio of 101.70, a P/E/G ratio of 2.75 and a beta of 1.36. The business's 50-day moving average price is $315.14 and its two-hundred day moving average price is $294.51. Insulet Corporation has a 1 year low of $225.37 and a 1 year high of $353.50. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. Insulet's revenue was up 32.9% compared to the same quarter last year. During the same period last year, the business earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Buying and Selling at Insulet

In other news, SVP Prem Singh sold 687 shares of the business's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares of the company's stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

Analysts Set New Price Targets

PODD has been the subject of a number of recent research reports. Raymond James Financial reissued an "outperform" rating and issued a $360.00 target price (up previously from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Royal Bank Of Canada increased their price objective on Insulet from $330.00 to $350.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. The Goldman Sachs Group started coverage on shares of Insulet in a report on Friday, May 30th. They issued a "buy" rating and a $380.00 target price on the stock. Truist Financial initiated coverage on shares of Insulet in a report on Monday, June 16th. They set a "buy" rating and a $365.00 price target for the company. Finally, Jefferies Financial Group reissued a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Sixteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $343.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.